Engineered mesenchymal stem cell-derived extracellular vesicles as programmable biomaterial platforms for liver fibrosis: design principles, manufacturing and clinical translation
Fanghong Wang, Kexiang Zhu, Xiaoliang Zhu, Jia Yao, Zongbin Sun, Xun Li · 2026
Read Engineered mesenchymal stem cell-derived extracellular vesicles as programmable biomaterial platforms for liver fibrosis: design principles, manufacturing and clinical translation by Fanghong Wang, Kexiang Zhu, Xiaoliang Zhu, Jia Yao, Zongbin Sun, Xun Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13631398.txt.
Description
Fanghong Wang and co-authors review how stem cell bubbles can be engineered into programmable medicine for liver scarring, in a 2026 paper. Mesenchymal stem cells shed tiny vesicles that carry healing signals, a cell-free therapy for fibrosis. Raw vesicles fall short: they home poorly, clear fast, and vary in cargo from batch to batch. Engineering answers at four levels, from editing the parent cell to dressing the vesicle's skin and loading its freight.
Tuned vesicles can calm the liver's scar-driving cells, reprogram the immune mood, restore the tissue scaffold, and spur new liver growth. Factory work is catching up: three-dimensional growth tanks, clean purification, and potency tests tied to how the drug works. The authors frame dose, safety, and rules as the last gates. Their paradigm treats the vesicle as a precision material, built to spec like any drug device.
Catalog record
| CREATOR | Fanghong Wang, Kexiang Zhu, Xiaoliang Zhu, Jia Yao, Zongbin Sun, Xun Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |